Daily Morning Note – 1 November 2021


China’s economy showed signs of further weakness in October as power shortages and surging commodity prices weighed on manufacturing. The official manufacturing purchasing managers’ index fell to 49.2, the National Bureau of Statistics said, the second month it was below the key 50-mark that signals a contraction in production. The non-manufacturing gauge, which measures activity in the construction and services sectors, dropped to 52.4, well below the consensus forecast. Meanwhile, cracks are beginning to show in China’s policy of stamping out all traces of Covid as soon as it appears. But Beijing remains committed to “Covid-zero,” at least through the Winter Olympics that begin in February. Here’s why China’s Covid crisis could be yet to come.



More travellers from the United States could soon be passing through Changi Airport to other parts of the region following a landmark agreement between Singapore Airlines (SIA) and US carrier United Airlines. The move could also lead to an additional option for Vaccinated Travel Lane flights to Singapore, and in the long term, paving the way for lower fares and more flights between Singapore and US, said experts. SIA had announced the partnership with United Airlines in an internal circular earlier this month. It said the carriers had signed a memorandum of understanding to work on supporting the resumption of connectivity between Singapore and the US.

Even as tighter virus containment measures resurface, Singapore banks’ third-quarter results are likely to reflect benign asset quality, declining credit costs and stable loan growth. Uneven recovery across the region could bump up loan moratoriums in countries such as Malaysia and Indonesia. DBS has booked around S$1.5 billion of general provisions – of which S$800 million was in excess of the minimum requirement set by the Singapore regulator – while OCBC and UOB have general provisions of around S$600 million and S$1.2 billion respectively.

Sembcorp Marine (Sembmarine) will be closely watched this week by analysts and investors like Temasek Holdings’ mandatory conditional general offer at S$0.08 per share closes on Wednesday (Nov 3) at 5.30 pm. While confidence in the beleaguered offshore and marine (O&M) company is very weak, its shares appear to be trading well below their intrinsic value. Provenance Capital – Sembmarine’s independent financial adviser (IFA) – estimates the company’s net asset value (NAV) as of Jun 30 adjusted for its recent rights issue stood at S$0.1437 per share.

SGX-listed Metech International Limited is pleased to announce that its joint venture company, Asian Eco Technology Pte. Ltd. DMT has also established strong working relationships with China’s top scientific research institutions such as Suzhou Institute of Nanotechnology and Nano-Bionics, Chinese Academy of Sciences, Xi’an Jiaotong University. Staffed by several industry experts, comprising professors, researchers and overseas scientists, DMT has built up strong technological capabilities and attained numerous intellectual property rights and patents.

Urban Redevelopment Authority (URA) has turned down an outline application for the proposed redevelopment of International Plaza in Tanjong Pagar under the Central Business District (CBD) Incentive Scheme. The outcome is seen as having implications for the ongoing collective sale tender for the property, which has a S$2.7 billion reserve price; if achieved, this would be the highest for a collective sale. The tender closes on Nov 30. URA unveiled the scheme in 2019 to spur owners of older predominantly office buildings in specific parts of the CBD to redevelop their properties into mixed-use projects. Owners would be allowed to build more gross floor area (GFA) – beyond the plot ratio in Master Plan 2019 or the approved plot ratio, whichever is higher (plot ratio is the ratio of GFA to site area). The idea is to inject a live-in population, liven up the district in the evenings and on weekends and rejuvenate the CBD.


Popular video game site Roblox had begun to restore service Sunday after a two-day outage that left millions of players without access to the online game world over the Halloween weekend.

US biotech firm Moderna said on Sunday that American officials have delayed approving its Covid-19 vaccine for teenagers to allow more time to better assess the potential risk of developing myocarditis, or heart inflammation. The US Food and Drug Administration (FDA) on Friday “informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination,” the biotech company said Sunday in a statement. The evaluation on whether to recommend Moderna’s vaccine for 12- to 17-year-olds could last until January 2022, the company said.

Chinese Foreign Minister Wang Yi told the United States not to “betray its promises” on Taiwan at a rare meeting on Sunday with Secretary of State Antony Blinken, as tensions run high over the island. Months of simmering tensions spiked in October after President Joe Biden declared that the United States would defend Taiwan in the event of an attack by Beijing – a statement seemingly at odds with long-held American policy towards the self-ruling island.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR

Sheng Siong Group Ltd – Market share spike

Recommendation: BUY (Upgraded); TP S$1.69, Last close: S$1.42;

Analyst Paul Chew

– 3Q21 revenue and PATMI beat our estimates. 9M21 revenue and PATMI at 85%/91% of forecasts. Gross margins was a record 29%.

– The closure of Jurong Fishery port and Pasir Panjang wholesale centre resulted in a surge in fresh food sales. Cautious consumers in visiting wet markets was another trigger.

– We raised FY21e PATMI by 15% to S$126.9mn. FY21e revenue forecast is lifted 11% and gross margins increased by 0.5% points to 28.3%. Our FY22e forecast is unchanged. The recent spike in cases is accelerating Sheng Siong’s market share in fresh food from wet markets. We believe this is a secular trend. Our target price is unchanged at S$1.69, based 5-year historical average of 25x PE. The target price is based on FY22e earnings, to reflect more normalised earnings as borders re-open. Upgrade to BUY from ACCUMULATE due to recent weakness in share price.

Apple Inc – Supply constraints, but demand strong

Recommendation: BUY (Maintained); TP US$187.00,

Last close: US$149.81; Analyst: Timothy Ang

– Full year revenue and PATMI in line at 100%/101% of our FY21 forecasts.
– Elevated freight costs and component shortages guided for the holiday season.
– Maintain BUY with an unchanged target price of US$187.00. Valuations based on DCF with a WACC of 5.8% and terminal growth of 3%. Demand for iPhone, iPad and Mac remain robust. iPhone 13 pre-orders were 20% above the iPhone 12 launched last year. We are estimating 2.8% iPhone sales growth in FY22e. We see potential near-term upside if Apple succeeds in its appeal to delay the App Store ruling coming into effect on 9 December. The ruling allows users in the US to pay outside the App Store, which could negatively impact revenue by 2% or gross profits by 4%.

Technical analysis: SG Market Outlook

3,200 resistance is impregnable

Analyst: Chua Wei Ren

– Singapore’s stock market rebounded last week. However, majority of the counters are facing tough resistance.

– The FTSE Straits Times Index rebounded and tested 3,200 psychological resistances but fails to break. Weekly chart shows a bearish pin bar which intensify a possible correction.

– Based on the technicals, the major bullish outlook remains intact.

POEMS Podcast: Let the Money Talk

Recent Podcasts:

Frasers Crentrepoint Trust – Today’s Trading Idea Ep 17
< Facebook Incorporation 3Q21 Results – SGX Company Insights Ep 38

Netflix Incorporation 3Q21 Results – SGX Company Insights Ep 37

Visit www.stocksbnb.com to learn more!

Join our Phillip Securities Research Telegram channel for the latest update on our stock coverage!

Click here to join: https://t.me/stocksbnb

Webinar Of The Week

Weekly Market Outlook: Del Monte, CICT, Keppel Corp, iX Biopharm &, SG Weekly

Date: 25 October 2021

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29 Keppel Corporation; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com